Cardiac Arrhythmias in Dravet Syndrome
- Conditions
- Epilepsy
- Registration Number
- NCT02415686
- Lead Sponsor
- Stichting Epilepsie Instellingen Nederland
- Brief Summary
SUMMARY
Rationale:
People with Dravet Syndrome (DS), a rare epilepsy syndrome, have a high risk of Sudden Unexpected Death in Epilepsy (SUDEP). Mouse models indicated that the responsible sodium channel mutation (SCN1A) not only alters cortical excitability but also increases the propensity to arrhythmias. Little is known yet about the prevalence of seizure-induced arrhythmias in human DS subjects.
Objective:
To assess the prevalence of cardiac arrhythmias in DS and to compare the prevalence of cardiac arrhythmias between DS subjects and subjects with other types of epilepsy.
Study design:
Observational study.
Study population:
Subjects with Dravet syndrome and a known pathogenic SCN1A mutation, seizure frequency ≥ 1/week (all seizure types except for absences or myoclonias), age ≥ 6 years and no signs of self-harm. Each case will be matched to two historical controls (age +/- 5 years) from the EEG databases of the participating centres. Only those controls with two or more recorded seizures will be matched to the cases.
Intervention:
Not applicable
Main study parameters/endpoints:
Ictal asystole Ictal bradycardia Ictal QT-shortening/lengthening
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Participation does not carry risks. The sensor is wearable and miniaturised, thus minimising discomfort. If this nevertheless may occur, the study can be terminated. This study provides specific tools to investigate the seizure-related heart rate response. Subjects may thus benefit from participation by identification of otherwise unknown arrhythmias. The rationale of the study (the high SUDEP risk and the evidence in animal studies for arrhythmic cause of sudden death) specifically applies to DS, a rare epileptic syndrome including minors and incapacitated persons. The investigators believe that the lack of risks, the potential diagnostic benefit, the minimal intervention with novel and wearable sensors and the possibility to terminate the study in case of discomfort, justifies the study in this patient group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 59
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ictal asystole (sinus arrest ≥ 3 s) or ictal bradycardia (< 2nd heart rate percentile for age) We will record heart rate patterns during seizures with miniaturized wearable EKG-monitors for 2 periods of 10 days
- Secondary Outcome Measures
Name Time Method Ictal QT lengthening or shortening We will record heart rate patterns during seizures with miniaturized wearable EKG-monitors for 2 periods of 10 days
Trial Locations
- Locations (3)
Stichting Epilepsie Instellingen Nederland (SEIN)
🇳🇱Heemstede, Achterweg 5, Netherlands
Great Ormond Street Hospital
🇬🇧London, South East, United Kingdom
Universität Bonn
🇩🇪Bonn, North Rhine-Westphalia, Germany